Physician profile
David Kantor
NPI 1801994926
$2,988.09
in general payments reported to CMS, 2019-2025
29 companies · $876 in 2025
The $876 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $79.06 · 2021: $24.24 · 2022: $497 · 2023: $575 · 2024: $675 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,125.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $486.07 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $439.67 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $427.82 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $223.85 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $211.12 | 2019-2025 | |
| Glaxosmithkline, LLC. | $165.11 | 2019-2025 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $126.76 | 2022-2024 | |
| Amgen INC. | $111.72 | 2023-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.65 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $95.07 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $61.95 | 2023 | |
| Sanofi-Aventis U.S. LLC | $55.25 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $49.84 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $45.34 | 2022-2025 | Rexulti |
| Esperion Therapeutics, INC. | $44.66 | 2022-2025 | Nexletol |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $42.19 | 2025 | Omnipod |
| Axsome Therapeutics, INC. | $34.71 | 2023 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $34.66 | 2020-2025 | Zoryve |
| Alnylam Pharmaceuticals INC. | $31.84 | 2024 | Onpattro |
| Takeda Pharmaceuticals U.S.A., INC. | $31.18 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.00 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $23.59 | 2025 | Voquezna |
| Sumitomo Pharma America, INC. | $23.18 | 2023 | Gemtesa |
| Nevro Corp. | $18.06 | 2024 | Senza |
| Janssen Pharmaceuticals, INC | $17.26 | 2023 | Xarelto |
| Ani Pharmaceuticals, INC. | $17.24 | 2024 | Purified Cortrophin Gel |
| Cook Medical LLC | $15.39 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.63 | 2024 | Uzedy |
| Dexcom, INC. | $13.28 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kantor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.